Viking Therapeutics Offers An Obesity Drug for Healthy Adults
Here are the key points about Viking Therapeutics' oral obesity drug VK2735: Early-Stage Trial Results: All doses of VK2735 demonstrate at least 10% weight loss compared with 4% for placebo. The trial is conducted in 28 days. And those with the highest dose of 100 mg lost an average of 8.2% of body weight.
An injection pen of Zepbound, Eli Lilly’s weight-loss drug, is displayed in New York City, December 11, 2023. [Photo: ...
Ozempic, Wegovy or Mounjaro: the battle of the weight-loss injections - As weight-loss injections emerge as key players in ...
Shares of Viking Therapeutics (NASDAQ:VKTX) jumped 22% Monday morning after the biotech firm reported promising results for ...
It seems like every day a new study emerges linking Ozempic and similar drugs to new health benefits. Ozempic is part of a drug class known as GLP-1 medications, which mimic gut hormones that help ...
Eli Lilly has seen tremendous growth from its new GLP-1 drugs, which people have been using for weight loss. Sales growth should continue as the company increases production and looks to win ...
Most of us are aware of the concept of drug side effects, which can be either negative or positive. The goal of any drug ...
Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two key drugs that missed expectations INDIANAPOLIS -- Eli Lilly is dialing ...
INDIANAPOLIS, Oct. 28, 2024 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2024 of $1.30 per share on outstanding ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback